Quarterly report [Sections 13 or 15(d)]

COMMITMENTS AND CONTINGENCIES (Details Narrative)

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)			3 Months Ended
	Oct. 04, 2023	Feb. 02, 2023	Mar. 31, 2026	Dec. 31, 2025	Mar. 11, 2025	Mar. 04, 2025	Jan. 05, 2024	Sep. 30, 2019	Dec. 10, 2015
Cash received			$ 211,911	$ 139,360
Compensation for services, description			As of May 14, 2021, the Company has entered into four consulting agreements. In compensation for services: (i) one consultant shall receive a remuneration amount of $10,000-$12,500 per month and has earned 1% of the Company’s majority owned subsidiary, BioCorRx Pharmaceuticals as of May 7, 2021 based on FDA clearance of Company’s IND application; consulting agreement terminated in April 2021 (ii) one consultant shall receive common stock equivalent to $1,375 on the last day of each month; (iii) two consultants shall receive common stock equivalent to $3,750 on the last day of each month; and (iv) one consultant shall receive a remuneration amount of $3,500 per month
Total consideration amount			$ 743,971
Charles River Laboratories, Inc. [Member]
Outstanding payable			$ 28,936
BICX Holding Company LLC [Member]
Common stock issued upon convertible debt			2,227,575
Convertible Promissory Note								$ 4,160,000
Total Interest Payment			$ 1,138,157
Issuance price per share			$ 2.00
Conversion agreement description			the Company’s financial statements as an amount due and owing to the Investor to be repaid within twelve (12) months of the closing of the Public Offering, or if the Public Offering is terminated or abandoned
Orange County Research Center [Member]
Payment of clinical services			$ 503,089
Pellecome [Member]
Attorney's fees			235,886
Attorney's fees received or awarded	$ 222,933	$ 222,933
Settelment amount					$ 418,000
Outstanding amount			$ 76,500
Interest rate			10.00%
Remaining commitment			$ 198,000
Pellecome [Member] \| January 5, 2024 [Member]
Attorney's fees received or awarded			332,503
Accrued interest			94,816
Consultant [Member]
Renumeration amount			$ 1,417
Issue of common stock to consultant			3,000
Alpine Creek [Member]
Royalty due			$ 91	91
Total consideration amount			1,531,926	$ 1,531,926
Payables to Alpine Creek									$ 1,215,000
Paid to Alpine Creek			$ 1,620,000
Payable commitment description			On any other proprietary implant distribution, that excludes the “treatment”, for alcohol and opioid addiction and for which no other payment is due, the Company shall pay 2.5% of the Company’s gross profit for implant distribution not to exceed $100 per sale. On or about January 1, 2021, Mr. Galligan acquired from Alpine Creek the rights to the royalty agreement by and between the Company and Alpine Creek. As of March 31, 2026 and December 31, 2025, there are no payments due
Payable per treatment sold									$ 100
Profit holding percentage									50.00%
Board of directors
Annual compensation							$ 200,000
Cash received						$ 15,000
Stock equivalent amount						$ 5,000